Ionis Pharmaceuticals (IONS) PT Raised to $68 at BMO Capital

Ionis Pharmaceuticals (IONS) Spinraza Approval Expected But a 'Major Positive', Laidlaw Says; PT Up To $65

Laidlaw analyst Yale Jen reiterated a Buy rating and raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to of $65.00 (from $59.00) announced the FDA approved Spinraza as a spinal muscular atrophy (SMA) treatment in pediatric and adult (late-onset) patients. IONS earned a... More

Needham & Company Reiterates Buy on Ionis Pharmaceuticals (IONS) Following FDA Approval

Needham & Company analyst Chad Messer reiterated a Buy rating and $64 price target on Ionis Pharmaceuticals (NASDAQ: IONS) and partner Biogen were granted FDA approval for SPINRAZA (nusinersen), a treatment for spinal muscular atrophy. SPINRAZA will have a broad label including both children and adults... More

Ionis Pharmaceuticals (IONS) PT Raised to $54 at Janney Montgomery Scott

Janney Montgomery Scott raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $54.00 (from $50.00) following FDA approval of SPINRAZA but maintained a Neutral rating.

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals... More

U.S. stock futures slightly higher after Christmas holiday

By Yashaswini Swamynathan

(Reuters) - U.S. stock index futures were slightly higher after the Christmas holiday, supported by small gains in U.S. crude prices.

U.S. crude was up 0.3 percent at $53.16 after a deal to limit supply came into effect on Sunday, boosting expectations of higher prices. [O/R]* The Dow Jones industrial average marked its seventh straight week of gains on Friday, feeding on... More

Ionis Pharmaceuticals (IONS) PT Raised to $47 at Leerink Partners

Leerink Partners raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $47.00 (from $40.00) following FDA approval of SPINRAZA but maintained a Market Perform rating.

For an analyst ratings summary and ratings history on Ionis Pharmaceuticals... More

BMO Capital Sees Ionis Pharma (IONS) and Biogen (BIIB) Trading Higher Following Broad Spinraza Approval

BMO Capital analyst Do Kim expects Ionis Pharma (NASDAQ: IONS) and Biogen (NASDAQ: BIIB) to trade higher Tuesday following an early Spinraza approval with a broad label, unrestricted by SMA type or SMN2 copy number.

"We see... More

Ionis Pharma (IONS) Gains Following FDA Approval for SPINRAZA

Ionis Pharma (NASDAQ: IONS) is gaining 8.6% in pre-open trade after the company and partner Biogen (NASDAQ: BIIB) announced FDA approval for SPINRAZA under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.... More

Biogen (BIIB) Receives FDA Approval for SPINRAZA to Treat SMA (IONS)

On Monday, the FDA approved Biogen's (NASDAQ: BIIB) SPINRAZA under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in the U.S. for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness.

In ENDEAR, a pivotal controlled clinical study, infantile-onset SMA patients treated with SPINRAZA achieved and sustained clinically meaningful improvement in motor function compared to untreated study participants. In addition, a greater percentage of patients on SPINRAZA... More